

## PCT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

Date of mailing (day/month/year) 26 February 2001 (26.02.01)	
International application No. PCT/NZ00/00135	Applicant's or agent's file reference 18040/4PCX104
International filing date (day/month/year) 21 July 2000 (21.07.00)	Priority date (day/month/year) 21 July 1999 (21.07.99)
Applicant HASHMI, Syed, Ziauddin et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 22 December 2000 (22.12.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer A. Karkachi
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number  
**WO 01/05411 A1**

(51) International Patent Classification: **A61K 35/56,**  
**A61P 29/00**

David [NZ/NZ]; 26c Peary Road, Mount Eden, Auckland  
1003 (NZ).

(21) International Application Number: **PCT/NZ00/00135**

(74) Agents: **SIMS, Anthony, W.** et al.; 29 Clarence Street,  
Private Bag 3140, Hamilton 2001 (NZ).

(22) International Filing Date: **21 July 2000 (21.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
336856 21 July 1999 (21.07.1999) **NZ**  
500630 27 October 1999 (27.10.1999) **NZ**  
505875 21 July 2000 (21.07.2000) **NZ**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **BOMAC  
LABORATORIES LIMITED** [NZ/NZ]; 102 Wiri Station  
Road and Hobill Avenue, Manukau City, Auckland 1701  
(NZ).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HASHMI, Syed,**  
**Ziauddin** [NZ/NZ]; 31 Watson Place, Papatoetoe, Auck-  
land 1701 (NZ). **LEECH, Wayne, Frederick** [NZ/NZ];  
2 Rochas Place, Manukau City, Auckland 1701 (NZ).  
**MCLAREN, Donald, George** [NZ/NZ]; 2 Turangi Road,  
Whitford, Auckland 1750 (NZ). **MCSPORRAN, Keith,**

**Published:**

- *With international search report.*
- *Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **COMPOSITIONS ADDRESSING INFLAMMATION AND/OR DEGENERATIVE DISORDERS**

(57) Abstract: The present invention is directed to compositions for primarily addressing degenerative complaints - in particular joint related conditions, such as arthritis and rheumatism, in which there may also be associated inflammation. Other potential uses are also discussed, as well as prophylactic and curative applications. Preferred embodiments incorporate green-lip mussel products (particularly GLME) with shark cartilage or chondroitin compounds. Plant and bark based antioxidants are employed in a number of embodiments.

WO 01/05411 A1

## COMPOSITIONS ADDRESSING INFLAMMATION AND/OR DEGENERATIVE DISORDERS

### TECHNICAL FIELD

The present invention is directed to compositions for addressing degenerative disorders and inflammation. Preferred embodiments of the invention comprises a sustained slow-acting composition which, when continually administered, exhibit anti-inflammatory effects though various embodiments may also exhibit analgesic effects, gastro-protective effects, a reduction in host-cell damage associated with inflammation, and may reduce cancerous tumours through antiangiogenesis. Differing embodiments may exhibit a number, or all, of these effects to varying degrees depending upon the degree and balance of synergism resulting from the selected components and ratios.

### BACKGROUND ART

The present invention was developed with the needs and problems associated with domestic animals in mind. In particular, domestic pets receive significantly more attention from humans than domesticated commercial species (e.g. livestock). The care and attention lavished on domestic pets also means that they tend to live to a significantly greater age than most commercially bred species and are thus more likely to exhibit the problems associated with old age. Such problems include cancer, and debilitating degenerative diseases.

In addition, animals are also susceptible to inflammation associated with various causes such as tissue damage or injury and, as for their human counterparts, some animals may also experience gastro-intestinal irritation from commonly used anti-inflammatories. As many domesticated pets are regarded by owners as family members, owners are often keen to address the various maladies that their pets exhibit

In most cases the solution is a curative remedial action after the problem has presented itself. While this may be effective for temporary afflictions such as acute infectious inflammation, longer term afflictions such as cancer and debilitating degenerative ailments have associated degenerative or other effects which are not usually fully reversible and quite often any remedial action is merely to attempt to control the further

spread of the affliction, or to ameliorate its effects on the animal. In some instances a partial improvement may be obtained, though there are problems associated with addressing an affliction after it has firmly established itself. As for humans, early diagnosis is often associated with a better prognosis for recovery or control.

5 Accordingly, a number of afflictions such as cancer or debilitating degenerative ailments (e.g. arthritis) may be more effectively controlled if preventative measures are taken. For instance there is evidence indicating that cartilage protecting agents may help protect against the occurrence of degenerative joint diseases and associated complaints. While there are varying forms of joint diseases, in general the complaint is accompanied  
10 by degeneration of cartilagenous material at the joints. The sooner action is taken against such degeneration, then the less the effects of the complaint will be. Thus, while an animal may still remain susceptible to joint related afflictions, preventative measures may protect against development of the complaint to any appreciable degree.

Similarly, inflammation at the joint is a factor in some degenerative joint diseases and  
15 thus some protection may also be provided by preventing inflammation in affected areas.

There are also a number of different types of cancers, though in particular the present invention is more focussed on those accompanied by tumourous growths. In many instances these tumours may be relatively benign though any tumourous growth is  
20 potentially serious. Again there is a link between early prognosis and recovery or effective control of the cancer and thus any preventative measure which can hinder the early growth or development of tumours will be of use.

For most animals, there is a limited number of products available which can be safely administered to afford a preventative or curative action towards these types of  
25 afflictions. Most animal remedies are based on pure chemicals for addressing a particular diagnosed chemical imbalance. Many of these contain side effects, and even for those that don't, it is generally not a recommended practice for their regular continued administration.

For domestic pets, there have been on-going improvements in food formulations, though  
30 again the primary emphasis has been on presenting a tailored balance of nutrients for different animals. A number of more recent formulations have addressed the elimination

of problem components, or have altered the foodstuff characteristics to counter known problems in pets – for example, altering the pH of certain pelletised cat foods to avoid urinary tract problems in adult cats. Most focus on various vitamins and minerals and may also increase or reduce specific amino acids present in the foodstuff. Some products have become quite specialised and one American product is specifically formulated for dogs undergoing chemotherapy, and includes high levels of n-3 fatty acids, which inhibit tumour growth.

However, there is a general need for a composition which can be administered on a regular basis to both healthy and afflicted animals and which can address one or more of a number of known, common, problems such as indicated above. Accordingly it is one aspect of the present invention to provide a composition, in a dosage form, or an alternate form, which can be administered regularly and in with relative safety to most domesticated pets, and particular mammalian species. At the very least, it is an object of the present invention to provide the public with a useful alternative to what is currently available.

Further aspects and advantages of the present invention will become apparent from the ensuing description which is given by way of example only.

#### **DISCLOSURE OF INVENTION**

According to one aspect of the present invention there is provided a composition for administration to animals including a combination of :

- (a) at least one anti-inflammatory agent selected from the group comprising
  - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
  - ii) shark cartilage; with
- (b) at least one enhancing agent selected from the group of:
  - i) a bark product or extract exhibiting antioxidant properties, and
  - ii) shark cartilage;

and wherein for a composition including just one member from each group, the selected members must be different.

According to a further aspect of the present invention there is provided a composition for administration to animals including a combination of :

- (a) at least one anti-inflammatory agent selected from the group comprising
- i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
  - ii) shark cartilage; with
- 5 (b) at least one enhancing agent selected from the group of:
- i) a bark or plant product or extract exhibiting any one of antioxidant, anti-arthritic, and anti-inflammatory properties, and
  - ii) shark cartilage;
- and wherein for a composition including just one member from each group, the selected
- 10 members must be different.

According to another aspect of the present invention there is provided a composition, substantially as described above, which includes either or both of a green-lipped mussel extract (GLME) and a pharmaceutically active green lipped mussel product, in combination with any one or more of:

- 15 shark cartilage, pharmacologically active shark extract, and chondroitin sulphate.

According to another aspect of the present invention there is provided a composition substantially as described above which includes an anti-inflammatory agent in combination with a chondroitin compound.

- 20 According to another aspect of the present invention there is provided a composition substantially as described above which includes as the anti-inflammatory agent either or both of shark cartilage and pharmacologically active shark cartilage extract in combination with any one or more of:

Enzogenol™, Pycnogenol™, a bark extract equivalent to Enzogenol™ or Pycnogenol™, chondroitin sulphate, and a chondroitin compound.

- 25 According to another aspect of the present invention there is provided a composition substantially as described above which includes, as an enhancing agent, Pycnogenol™.

According to another aspect of the present invention there is provided a composition substantially as described above which includes one or more anti-oxidants other than Enzogenol or equivalent bark extracts.

- 30 According to another aspect of the present invention there is provided a composition substantially as described above in which an anti-oxidant is vitamin E.

According to another aspect of the present invention there is provided a composition substantially as described above in which includes deer velvet or a pharmacologically active extract thereof.

5 According to another aspect of the present invention there is provided a composition substantially as described above in which includes additional glycosaminoglycans than those present in the selected anti-inflammatory or enhancing agents.

According to another aspect of the present invention there is provided a composition substantially as described above in which green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product in sufficient amount to provide  
10 gastro-intestinal protection against irritation by other components in the composition.

According to another aspect of the present invention there is provided a composition substantially as described above which also includes any one or more of the following components:

15 a vitamin, glycine, lysine, methionine, glutamic acid, tyrosine, and compounds providing in a pharmacologically acceptable form one or more of the following elements: manganese, zinc, iron, magnesium, selenium, calcium, copper, potassium, cobalt.

20 According to another aspect of the present invention there is provided a composition substantially as described above which includes one or more pharmacologically active substances.

According to another aspect of the present invention there is provided a composition substantially as described above in which a pharmacologically active substance is an anti-inflammatory other than those listed in claim 1.

25 According to another aspect of the present invention there is provided a composition substantially as described above formulated to be suitable for addressing any one or more of the following conditions in animals: inflammation, arthritis, chronic joint pain.

According to another aspect of the present invention there is provided a composition substantially as described above in any one or more of the following forms:  
30 as a bolus or tablet, in a capsule, as a slow release implant, as a liquid composition, as a gel, and as a paste.

According to another aspect of the present invention there is provided a composition substantially as described above formulated for use with non-human mammals.

According to a further aspect of the present invention there is provided a method for addressing joint problems in non-human animals consisting of the administration of a composition as claimed in any one of the preceding claims.

According to another aspect of the present invention there is provided a method substantially as described above in which the method of administration is oral.

According to a further aspect of the present invention there is provided the use of any two or more of:

- i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product,
- ii) shark cartilage and/or pharmacologically active shark cartilage extract; and
- iii) Enzogenol™, and/or equivalent bark extract.

in the preparation of a composition for use in addressing any one or more of:

- a) inflammation;
- b) degenerative joint complaints;
- c) other cartiligenous degeneration;
- d) gastrointestinal sensitivity or irritation;
- e) cancerous tumours;

The present invention has been developed with the needs of domesticated pets, and primarily mammalian species, in mind though it is also envisaged that the present invention is applicable to commercially bred species. However, while tablets or foodstuffs may be regularly administered or fed to pets or stabled animals, the problems associated with regular administration to sheep, cattle, and other livestock, may preclude regular use of the present invention with those species. However this does not mean that the present invention is detrimental, and therefore cannot be administered to such species or animals.

Preferred embodiments of the present invention focus around the use of three components, or equivalents thereof. These comprise green lipped mussel extract (GLME), shark cartilage and ENZOGENOL™. Each of these components alone is known to exhibit a number of useful properties, though it has been found that varying

combinations of these components can yield a significant improvement in the effectiveness of these components alone, and also render the resulting combination useful for addressing a number of complaints.

For instance, green lipped mussel extract (GLME) comprises extractions from the shellfish species *perna canaliculus*, a mollusc found on the shores of New Zealand. This is a convenient means for including active components from the green lipped mussel, though other forms of green lipped mussel and its products (preferably pharmacologically active) can be used. This mollusc has been found to contain a number of components exhibiting anti-inflammatory activity and includes small amounts of glycosaminoglycans which have been shown to be beneficial for maintaining the integrity of cartilage and bone. Accordingly, green lipped mussel extract has been used for alleviating arthritic complaints, including degenerative joint diseases.

Green lipped mussel extract (GLME) where used in various embodiments of the present invention is preferentially that obtained from extraction processes from live, or recently killed mussels. Procedures such as outlined in granted patents to the inventor Stuart J McFarlane may be followed, though the product may preferentially be obtained from McFarlane Laboratories NZ Ltd., of New Zealand.

The same inventor has also pursued further patent applications directed to extracting specific targeted compounds from green lipped mussels, and re-combining or using these in other preparations. An example is the disclosure of US 4,455,298 (NZ 188489). Such extracts are also considered to be among the acceptable substitutes for green lipped mussel extract (GLME) for use in the present invention.

Shark cartilage has also been used by persons suffering from disorders such as cancer and arthritis and there it appears that it is useful in addressing these complaints. Identified active components include chondroitin sulphate, and glycosaminoglycans. Various shark cartilage products may be used, though preferentially include or retain active quantities of these components.

A further component which can be considered is a bark or plant extract exhibiting antioxidant properties. Preferably the antioxidant activity exceeds that of vitamin E. One product which has been mentioned is ENZOGENOL™, a proprietary composition manufactured by Enzo Nutraceuticals Limited, of Christchurch, New Zealand, and

comprises an extract from the bark of *Pinus radiata* which is rich in anti-oxidants. Other bark products exist with PYCNOGENOL™, another proprietary product being an acceptable alternative. There is evidence establishing that oxidant and free radical damage can be addressed by this formulation. Both oxidant and free-radical damage have been shown to be involved in both premature ageing, and in particular, joint disease. Equivalent products to ENZOGENOL™ or PYCNOGENOL™ may be substituted, though the preference is for these products as they contain components other than antioxidants that may further enhance the properties of the product.

As previously indicated, it has been indicated that a significant useful improvement can be made by combining two or more of the three listed components. The selected combination will have some effect on the focus and activity of the resulting combination, and this will become more apparent from the following description.

One possible combination is green lipped mussel (GLM, and preferably an extract) with shark cartilage. This combination is of use as an anti-inflammatory, though in particular is useful for addressing arthritic complaints and degenerative joint problems. For instance, green lipped mussel and its preferred extracts include glycosaminoglycans which help protect cartilage and bone. Preferred GLM extracts also exhibit an anti-inflammatory effect. Most arthritic complaints and degenerative joint disorders are known to involve an associated inflammation in the joint region and thus extracts of GLM that have demonstrated effectiveness in these type of disorders have been at least partly attributable to the anti-inflammatory characteristics.

Shark cartilage contains higher levels of glycosaminoglycans which augment the cartilage protective effects of GLM products and extracts alone. This is further augmented by the presence of chondroitin sulphate, another cartilage protecting component. The collagen also present in shark cartilage further enhances the effectiveness of the combination.

Shark cartilage also possess some antiangiogenetic properties which also affords the combination and additional properties in addressing cancer tumour formation. It is also considered that the same property may also further enhance the ability of the combination to address, both preventatively, and curatively (to varying degrees) joint and cartilage problems – particularly mobility related ailments.

Enhancing agents such as ENZOGENOL™, PYCNOGENOL™ or equivalent bark extracts, may also be combined with either or both of GLME and shark cartilage. Both GLME and shark cartilage possess anti-inflammatory properties. The combination with ENZOGENOL™, with its anti-oxidant and anti-free radical properties, enhances the usefulness of these anti-inflammatories in addressing a number of disorders, and preventing the formation of other problems. For instance, inflammation is generally the consequence of a defensive action of the body and in some instances is accompanied by a significant amount of oxidants in the inflamed regions. These oxidants often include nitrous oxide, varying peroxides and a number of other substances which exhibit a strong localised anti-microbial effect. However, the effectiveness of their action is not always confined to foreign bodies. These oxidants produced by the body are also known to exhibit a negative effect on the host's own cells, and it is known that some oxidant species can disrupt host cell DNA sequences. Current theories consider this to be the first transformational change to occur in a number of forms of cancer, and thus addressing this problem will represent a preventative technique towards the establishment of a number of forms of cancer.

Anti-oxidants, such as those provided in ENZOGENOL™, can reduce damage to the host's own cells, but without any significant decrease in the effectiveness of remaining oxidants in addressing microbial invaders and other foreign material. In some respects the anti-oxidants may be considered to have a regulating effect and tend to mop up excess oxidants which have been produced beyond the actual needs of the body.

Accordingly, the combination of a bark based anti-oxidant product with an anti-inflammatory, produces a substantially enhanced useful overall effect in reducing not only the amount of inflammation, but negative side effects associated with inflammation. Other factors may be at work though the use of products such as PYCNOGENOL™ or ENZOGENOL™ appear to confer the desired characteristics.

Further, the reduction in likelihood of an oxidant induced cancer transformation, coupled with the antiangiogenetic properties of shark cartilage, renders this a useful combination for reducing the probability of cancer formation.

Further, it will be appreciated that the combination of all three can yield a highly useful product which can help simultaneously address a number of afflictions which affect animals, and which become more prevalent in older animals.

Another anti-oxidant which may be used in varying embodiments of the present invention is vitamin E. Other anti-oxidants are also known, and both these and/or vitamin E may be used in varying embodiments including these combining GLM products and extracts with shark cartilage. However, preferred embodiments would  
5 include a bark based antioxidant as the preferred anti-oxidant of choice, though it should be also appreciated that not all uses of varying embodiments will focus on inflammation and its side-effects, and thus lower levels of additional anti-oxidant activity may be provided.

Other enhancing agents include plant based products exhibiting antioxidant properties,  
10 though may additionally, or alternatively, exhibit anti-inflammatory or anti-arthritic properties. In this later case, the preference is still to include an antioxidant, or to select a material also exhibiting antioxidant properties. One possibility is to include these other enhancing agents in combination with a bark based antioxidant such as ENZOGENOL™ or PYCNOGENOL™. As a gauge of antioxidant activity, pharmacological  
15 activity comparable to or exceeding vitamin E is desirable, or alternatively an activity comparable to ENZOGENOL™ or PYCNOGENOL™.

As can be appreciated, the varying combinations which have been described provide enhanced activity and properties over the individual components. The result is a range of embodiments which may be used in a number of similar roles, but which may exhibit  
20 slightly enhanced activity in one role over another.

Some of these components possess other useful properties which may extend the usefulness of various combinations. For instance, GLM products and extracts are known to be useful in preventing, alleviating, or treating gastro-intestinal irritation. Accordingly, compositions of the present invention which include GLM and/or its  
25 extracts may also be used as a carrier for, or as part of, compositions containing irritant substances just as GLME alone is used in such a role. This further extends the usefulness and flexibility of embodiments of the present invention.

For instance, many current fast-acting anti-inflammatories are irritating to the stomach. While embodiments of the present invention generally include sufficient anti-  
30 inflammatory activity, when administered over sustained periods, to preclude the use of most existing pharmaceutical anti-inflammatories, there may be instances where the user may wish or need to include one of these existing faster acting compounds. Including

such a substance in such embodiments of the present invention may not only reduce the amount of the added anti-inflammatory which needs to be included, but the counter irritant effects of GLME can help reduce the side-effects from the administration of an added anti-inflammatory which may cause irritation.

- 5 There are a number of other pharmaceuticals which exhibit irritant properties, and the co-administration, or co-compounding, of embodiments of the present invention with those substances is also a technique within the scope of the present invention. In particular, embodiments of the present invention may find use for administration during chemotherapy which tends to have a number of significant negative side effects.
- 10 Embodiments of the present invention may also include other substances which are known to have a beneficial effect. One such substance is deer velvet for which a large amount of anecdotal, but little clinical, evidence exists of its effectiveness. The little clinical work which has been performed suggests that deer velvet administered orally can address problems associated with high blood pressure, as well as having both
- 15 immuno-stimulatory and anti-inflammatory properties. The inclusion of deer velvet would therefore augment such properties already existing in various embodiments of the present invention.

It is also envisaged that varying embodiments may also include manganese ascorbate and/or S-adenosylmethionine (aka S-adenosyl-L-methionine 1,4 butane disulfonate).

- 20 This latter compound is also known to promote joint mobility, while the former is involved in the biosynthesis of glycosaminoglycans. These can enhance the action of other components in preferred embodiments of the invention addressing debilitating joint ailments.

- As mentioned previously, the present invention may take varying forms. It is envisaged
- 25 that a common form of the invention is as an oral dosage form. This may be as a pill, tablet, capsule, etc. Liquid formulations may also be produced, as may other types of solid formulations. In particular, an animal foodstuff is envisaged. Each of these different forms may be prepared according to standard existing techniques, and which include the components of the various embodiments of the present invention.

## BEST MODES FOR CARRYING OUT THE INVENTION

### Example 1: Compositions for adult dogs

This comprises a tablet (or similar dosage form) or dietary foodstuff which includes green lipped mussel extract in combination with shark cartilage. Ideally, the composition also includes a range of vitamins and trace minerals in a balanced proportion, ideal for targeted animal range. Different embodiments may contain different ratios, depending upon the size, type, or age of the animal.

### Example 1a: Constituents

In this embodiment, a dosage form, which may take the form of a pellet, capsule or tablet etc, may contain:

Green Lipped Mussel Extract	50 – 200 mg
Shark cartilage	50 – 200 mg
Vitamin mix-optional but where included:	200 ± 200 mg

Which may, for example, consist of:

Vitamin A	2000-3000 iu
Vitamin D3	300-500 iu
Vitamin E	20-30 iu
Vitamin K3	0.5-0.75 mg
Thiamine (Vitamin B1)	1-1.5 mg
Riboflavin	2-3 mg
Pyridoxine	0.5-0.75 mg
Panthothenic acid	2-3 mg
Niacin	7-10.5 mg
Biotin	0.1-0.75 mg
Vitamin B12	22-150 µg
Folic acid	0.1-0.15 mg
Iron	12-20 mg
Copper	1.5-2.5 mg
Cobalt	0.25-0.4 mg
Manganese	3-5 mg

	Zinc	25-40 mg
	Iodine	0.5-0.75 mg
	Selenium	0.075-0.125 mg
	Calcium	10-20 mg
5	Manganese ascorbate	optional
	S-adenosylmethionine	optional

The dosage form may also be incorporated into a food product, such as a pellet, which can be administered for consumption by the animal. Such dosage forms could also be seeded throughout pelletised animal foods – lower dosage forms may be prepared for such applications.

For the embodiment above, a typical suggested once daily dosage is:

up to 15 kg	1 tablets
15 – 30 kg	2 tablets
over 30 kg	3 tablets

15 This example is illustrative only. The vitamin mix is illustrative of a typical balance for adult dogs, but can be varied (and components added or eliminated) in different embodiments for other species and ages.

#### Example 1B

In this embodiment, a dosage form, which may take the form of a pellet, capsule or tablet etc, may contain:

	Green Lipped Mussel (preferably dried or powdered) or extract thereof:	50 – 200 mg
	Shark cartilage (preferably dried or powdered) or chondroitin sulphate or condroitin containing substance	50 – 200 mg
25	Vitamin mix (as above in Example 1A)	optional

The dosage form may also be incorporated into a food product, such as a pellet, which can be administered for consumption by the animal. Such dosage forms could also be

seeded throughout pelletised animal foods – lower dosage forms may be prepared for such applications.

For the embodiment above, a typical suggested once daily dosage is:

	up to 15 kg	1 tablets
5	15 – 30 kg	2 tablets
	over 30 kg	3 tablets

This example is illustrative only. The vitamin mix is illustrative of a typical balance for adult dogs, but can be varied (and components added or eliminated) in different embodiments for other species and ages.

#### 10 Example 2

This comprises a dosage form combining green lipped mussel with an anti-oxidant, and is of particular use for preventing or addressing inflammation.

In this embodiment a typical dosage form may contain:

15	Green lipped mussel extract (or pharmacologically active green lipped mussel product)	50 – 200 mg
	ENZOGENOL™ or PYCNOGENOL™	5 ± 2 mg
	Anti-inflammatory plant extract (optional)	0 – 500 mg
	Vitamin mix (see example 1a)	200 ± 200 mg.

- 20 As for Example 1, the dosage form may take different forms, including capsules, tablets, pellets, and even liquid forms. Liquid forms would generally include an acceptable carrier, and may include inert oils such as comestible vegetable oils, and fish oils.

#### Example 3

- 25 This example combines shark cartilage with a bark based antioxidant. While this combination is useful for addressing inflammation, it is directed more to the prevention, and/or addressing arthritic complaints and degenerative joint diseases and afflictions.

In this embodiment the dosage form may contain:

Shark cartilage	50 – 200 mg
-----------------	-------------

- |   |   |               |
|---|---|---------------|
|   | ENZOGENOL™ or PYCNOGENOL™   | 2 – 10 mg.    |
|   | Anti-arthritic and/or anti-inflammatory<br>Plant extract (optional:                                 | 0 – 500 mg    |
| 5 | Vitamin mix (see example 1a)<br>preferably including adenosylmethionine<br>and manganese ascorbate. | 200 ± 200 mg. |

---

Dosages and varying dosage forms, are as for the preceding examples.

#### Example 4

- 10 This embodiment includes deer velvet in addition to the compositions of any of the preceding examples. To a formulation as described in any of examples 1 through 3, there is also included deer velvet in the amount of  $25 \pm 10$  mg. Preferably this is dried deer velvet, which has been prepared by a method avoiding substantial degradation of included natural components.

Dosing and administration is as per Example 1 herein.

- 15 Example 5: for older or arthritic animals, or animals exhibiting mobility problems

These embodiments may also be in dosage forms, or foodstuffs. This range of embodiments are targeted at older animals, and particularly those that may be showing joint problems or arthritis.

- 20 These embodiments combine green lipped mussel extract with shark cartilage or extracts thereof. Ideally, the shark cartilage, or any extract thereof, should include glycosaminoglycans. These two active components act as powerful anti-inflammatories, and provide anti-inflammatory action over the use of the green lipped mussel extract alone.

- 25 Optionally but ideally also, deer velvet or extract thereof is included in the these formulations.

Ideally also, these embodiments will also include ENZOGENOL (proprietary formulation of anti-oxidants).

Example 5a: Constituents

Each tablet contains:

	Green Lipped Mussel Extract	175 ± 75 mg
	Deer Velvet	25 ± 10 mg
5	Shark Cartilage	100 ± 50 mg
	ENZOGENOL (™) or PYCNOGENOL™	5 ± 2 mg
	Vitamin mix (see example 1a)	200 ± 200 mg

Suggested once daily dosage as per example 1a.

May be fed in conjunction with Example 1a formulation. Can be administered directly  
10 into the mouth or added to the food.

Example 6: for cats

The preferred embodiment for cats will include green lipped mussel extract. This acts  
in the role of an anti-inflammatory to improve mobility, as well as relief from sore and  
arthritic joints. Again, preferred embodiments of this range will also include a balanced  
15 range of vitamins and trace minerals for cats.

Example 6a: Constituents

Each tablet contains:

	Green Lipped Mussel Extract	
	(or pharmacologically active	
20	green lipped mussel product –	
	quantity of such products may	
	need to be varied according to	
	activity)	175 ± 75 mg
	Either or both of:	
25	i) ENZOGENOL™ or PYCNOGENOL	5 ± 2 mg
	ii) shark cartilage	20 – 175 mg
	Taurine	100 ± 50 mg
	Potassium gluconate	70 ± 20 mg

Thiamine hydrochloride	25 ± 10 mg
Yeast	50 ± 20 mg
Dextrose (as a tableting agent)	
Vitamin mix (see example 1a)	optional

- 5 This composition can provide some additional benefit for cats. Taurine, an essential dietary ingredient in cats, is fundamental in preventing heart and eye disease. Taurine is also an important part of bile in the cat's digestive system. Potassium Gluconate helps prevent hypocalcaemia, a common diet related deficiency in cats.

- 10 Thiamine helps prevent diseases related to thiamine deficiency such as diarrhoea, kidney disease and polioencephalomalacia. Yeast provides a rich source of B vitamins and other natural products. Dextrose is included as a tableting agent, instead of the more commonly used lactose, because many cats are lactose intolerant.

Suggested once daily dosage

	2.5 kg	1 tablets
15	> 2.5 kg	2 tablets

Can be administered directly into the mouth or added to the food.

It is also possible to use the compositions of examples 1 through 5 for cats.

Example 7

Trials were conducted using tablets on a number of different breeds of dog.

20 *Analysis of tablets used in trial*

Active ingredients:	per tablet
Green lipped mussel extract	175mg
Shark cartilage	100mg
ENZOGENOL™	5mg

- 25 The natural ingredients contain traces of the following vitamins and minerals:

Vitamin C	Tyrosine
Vitamin D3	Potassium

5	Vitamin B1	Cobalt
	Vitamin B2	Manganese
	Niacin	Zinc
	Vitamin B6	Iron
	Vitamin B12	Magnesium
	Glutamic acid	Selenium
	Glycine	Calcium
	Lysine	Copper
	Methionine	

- 10 The trial was an open assessment. The effect of the treatment was based on the owner's subjective observation of the dogs mobility and vitality. The patients chosen for treatment were dogs with lameness and/or diminished mobility due to pain from chronic arthritis. The recommended dose was 1 tablet per 10 kg bodyweight. The results of the trails are summarised in table 1. The effect is described as 0 : no effect, 1+ : some
- 15 improvements, 2+ : good effect and 3+ : very good effect.

From table 1 it appears, that the recorded effect of the product in 12 out of 16 cases is good or very good. Typically there was seen improvement of mobility within 5 to 14 days, and especially it was noted by the clients that the dogs showed more vitality and improved well-being. This was most remarkable in geriatric patients.

- 20 The initial effect stabilises after 1 to 2 months. The owner also gets used to the better mobility of his dog. A certain depot-effect seems to be built up, which may last for weeks or months. Therefore it is recommended that there is a somewhat (50%) lower maintenance dose after initial dosing for approximately 2 months. After this period further improvement cannot be expected and the dog will stay in status quo.
- 25 It appears from table 1, that the indications mainly have been arthritis in different joints like elbow, knee, spondylosis etc. Clinically we have in a few cases observed diminished crepitation in arthritic joints, probably due to better lubrication. We have also observed better vitality in many cases.

- During the trial were used tablets from 3 different batches. There was no noted
- 30 difference as to quality or effect.

Table 1: Race, indication, effect and number of glasses consumed in 16 dogs treated for joint pain

Race	Years	Indication	Dose/Day	Effect	Kg	Used glasses of 100
Labrador	11	Arthroses+skin	3	3+	34	5
Labrador	14	Elbow arthrosis	3	3+	26	5
Labrador	12	Hip dysplasia	2	3+	22	4
Lab/schæfer	13	Hip dysplasia/knee	2	3+	20	5
Fox terrier	14	Shoulder arthrosis	1	1+	8	1*
Dachshund	14	Spondylosis	1	3+	8	3
Shetl. sheepdog	14	Elbow arthrosis	1	0	12	0**
Finsk Spids	10	Spondylosis	2	3+	18	3
Weimaraner	6	Cruc.rupt.chron.	3	2+	26	1
Border Collie	0.5	Cruc.rupt.acute	1	2+	12	2
Labrador	0.4	Hip dysplasia	1	3+	18	3
Golden Retriever	8	Knee arthros., skin	3	2-3+	32	4
Rottweiler	4	Elbow arthrosis	3	2	38	4
Schæfer	14	Spondylosis	3	2+	32	3
Labrador	10	Elbow arthrosis	3	1+	28	6
Boxer	6	Spondylosis	3	1+	31	2

\* Euthanised after 1 month due to Cushing syndrome.

\*\* Medication stopped after 1 week due to polydipsia.

Generally there were no observed adverse side-effects. One dog showed polyuri and polydipsia after 1 week treatment. The owner stopped treatment with the trial product and the symptoms disappeared. The dog was not examined as to the cause of the PU/PD, so the condition might have been due to other reasons.

## 5 Conclusion

Chronic arthritis is very difficult to treat. The clinical response has been so positive, that this composition should be considered in future treatment of chronic arthrosis, of patients with loss of vitality and unspecified stiffness of joints or diminished mobility. For many dogs treatment with NASID or corticosteroids is problematic and in these cases many clients will prefer a natural, alternative treatment when a positive effect can be observed.

### Example 7

Following are the results of further efficacy tests performed using various embodiments of the present invention.

No.	Dog Breed	Sex	Age (year)	Weight (kg)	Intake (tabs)	Symptom	Evaluation
1.	Beagle	M(n)	9	18.0	2	Disk herniation	No effect
2.	Akita	M	11	31.8	3	Knee arthritis	Remarkably effective
3.	Miniature Dachshund	M(n)	9	8.3	1	Coxa aplasia	Effective
4.	Mix	M	11	9.8	1	Patella luxation	Remarkably effective
5.	Yorkshire Terrier	F	13	2.2	1	Coxa aplasia	Slightly effective
6.	Sheltie	M	13	11.8	1	Coxa aplasia	Effective
7.	Mix	F(h)	11	17.4	2	Knee arthritis	No effect
8.	Sheltie	F(h)	11	12.0	2	Arthritis	Effective
9.	Sheltie	F	7	11.8	1	Osteoarthritis of spine	Remarkably effective
10.	Pomeranian	F(h)		4.7	1	Coxa aplasia	No effect
11.	Chow Chow	F	3	38.2	3	Carpus Arthritis	Remarkably effective
12.	Mix	F	3	29.7	2	Traumatic Patella luxation	Remarkably effective
13.	Pekinese	F	14	5.6	1	Coxa aplasia	No effect
14.	Mix	F	6	13.2	1	Knee Arthritis	Effective
15.	Sheltie	F	8	17.0	2	Arthritis	No effect
16.	Pomeranian	F	3	3.7	1	Patella luxation	Effective
17.	Maltese	F(h)	10	4.7	1	Arthritis	Remarkably effective
18.	Bernese Mountain dog	F	1	30.00	3	Arthritis	Remarkably effective
19.	Mix	M	5	13.2	1	Left hind foot lameness	Remarkably effective

No.	Dog Breed	Sex	Age (year)	Weight (kg)	Intake (tabs)	Symptom	Evaluation
1.	Beagle	M(n)	9	18.0	2	Disk herniation	No effect
2.	Akita	M	11	31.8	3	Knee arthritis	Remarkably effective
3.	Miniature Dachshund	M(n)	9	8.3	1	Coxa aplasia	Effective
4.	Mix	M	11	9.8	1	Patella luxation	Remarkably effective
5.	Yorkshire Terrier	F	13	2.2	1	Coxa aplasia	Slightly effective
6.	Sheltie	M	13	11.8	1	Coxa aplasia	Effective
7.	Mix	F(h)	11	17.4	2	Knee arthritis	No effect
8.	Sheltie	F(h)	11	12.0	2	Arthritis	Effective
9.	Sheltie	F	7	11.8	1	Osteoarthritis of spine	Remarkably effective
10.	Pomeranian	F(h)		4.7	1	Coxa aplasia	No effect
11.	Chow Chow	F	3	38.2	3	Carpus Arthritis	Remarkably effective
12.	Mix	F	3	29.7	2	Traumatic Patella luxation	Remarkably effective
13.	Pekinese	F	14	5.6	1	Coxa aplasia	No effect
14.	Mix	F	6	13.2	1	Knee Arthritis	Effective
15.	Sheltie	F	8	17.0	2	Arthritis	No effect
16.	Pomeranian	F	3	3.7	1	Patella luxation	Effective
17.	Maltese	F(h)	10	4.7	1	Arthritis	Remarkably effective
18.	Bernese Mountain dog	F	1	30.00	3	Arthritis	Remarkably effective
19.	Mix	M	5	13.2	1	Left hind foot lameness	Remarkably effective

No.	Dog Breed	Sex	Age (year)	Weight (kg)	Intake (tabs)	Symptom	Evaluation
20.	Shiba	M	12	10.5	2	Osteoarthritis of spine	Exacerbation
21.	Chihuahua	M(n)	2		1	Arthritis	Remarkably effective
22.	Mix	F(h)	12	13.3	1	Patella luxation	No effect
23.	Golden retriever	F	5	26.8	2	Ligament rupture	Judgement impossible
24.	Dachshund	F(h)	8	4.3	1	Arthritis	Slightly effective
25.	Mix	F(h)	12	8.7	1	Osteoarthritis of spine	Remarkably effective
26.	Mix	M(n)	12	15.7	2	Osteoarthritis of spine	Judgement impossible
27.	Mix	F(h)	9	19.9	2	Coxalgia	Remarkably effective
28.	Pug	F	8	7.2	1	Osteoarthritis of spine	No effect
29.	Maltese	F	18	3.0	1	Left shoulder subluxation	Remarkably effective
30.	Pomeranian	F(h)	11	6.0	1	Both hip arthritis deformans	Remarkably effective
31.	Mix	F(h)	9	13.2	1	Both hip arthritis deformans	Remarkably effective
32.	Shih Tzu	M(n)	6	8.3	1	Right patella luxation	Remarkably effective

No.	Dog Breed	Sex	Age (year)	Weight (kg)	Intake (tabs)	Symptom	Evaluation
20.	Shiba	M	12	10.5	2	Osteoarthritis of spine	Exacerbation
21.	Chihuahua	M(n)	2		1	Arthritis	Remarkably effective
22.	Mix	F(h)	12	13.3	1	Patella luxation	No effect
23.	Golden retriever	F	5	26.8	2	Ligament rupture	Judgement impossible
24.	Dachshund	F(h)	8	4.3	1	Arthritis	Slightly effective
25.	Mix	F(h)	12	8.7	1	Osteoarthritis of spine	Remarkably effective
26.	Mix	M(n)	12	15.7	2	Osteoarthritis of spine	Judgement impossible
27.	Mix	F(h)	9	19.9	2	Coxalgia	Remarkably effective
28.	Pug	F	8	7.2	1	Osteoarthritis of spine	No effect
29.	Maltese	F	18	3.0	1	Left shoulder subluxation	Remarkably effective
30.	Pomeranian	F(h)	11	6.0	1	Both hip arthritis deformans	Remarkably effective
31.	Mix	F(h)	9	13.2	1	Both hip arthritis deformans	Remarkably effective
32.	Shih Tzu	M(n)	6	8.3	1	Right patella luxation	Remarkably effective
33.	Miniature Pinscher	M	17	1.7	1	Left elbow arthritis deformans	Judgement impossible
34.	Pomeranian	M(n)	7	6.3	1	Left shoulder subluxation	Remarkably effective
35.	Mix	F	12	14.1	1	Right hip and knee subluxation	Effective
36.	Cavalier King Charles Spaniel	F	3	7.9	1	Left knee subluxation	Effective

<b>Remarkably effective</b>	48%	16/33
Every parameters were improvements, or more than 2 parameters improved 2 points		
<b>Effective</b>	21%	7/33
More than 2 parameters improved 1 point		
<b>Minor response effective</b>	6%	2/33
More than 1 parameters improved 1 point		
<b>Exacerbation</b>	3%	1/33
Taking a turn for the worse		
<b>No effect</b>	21%	7/33
No improvement		
<b>Disable judgement</b>	3 cases	
We could not evaluate (because of discontinuance)		

Aspects of the present invention have been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope thereof as defined in the appended claims.

33.	Miniature Pinscher	M	17	1.7	1	Left elbow arthritis deformans	Judgement impossible
34.	Pomeranian	M(n)	7	6.3	1	Left shoulder subluxation	Remarkably effective
35.	Mix	F	12	14.1	1	Right hip and knee subluxation	Effective
36.	Cavalier King Charles Spaniel	F	3	7.9	1	Left knee subluxation	Effective

Remarkably effective	48%
Effective	21%
Slightly effective	6%
Exacerbation	3%
No effect	21%
Judgement impossible	3 cases

Breed	Sex	Age	Wt	Score	Clinical Observation	Remarks
犬種	性別	年齢	体重	投与量	症状	効果判定
1 ビーグル	去勢	9	18.0	2	椎間板ヘルニア	無効
2 秋田	オス	11	31.8	3	膝関節炎	著効
3 ミニチュアダックス	去勢	9	8.3	1	股関節形成不全症	有効
4 雑種	オス	11	9.8	1	膝蓋骨脱臼	著効
5 ヨーキー	メス	13	2.2	1	股関節形成不全症	やや
6 シェルティー	オス	13	11.8	1	股関節形成不全症	有効
7 雑種	避妊	11	17.4	2	膝関節炎	無効
8 シェルティー	避妊	11	12.0	2	関節炎	有効
9 シェルティー	メス	7	11.8	1	変形性脊椎症	著効
10 ポメラニアン	避妊		4.7	1	股関節形成不全症	無効
11 チャウチャウ	メス	3	38.2	3	手根関節炎	著効
12 雑種	メス	3	29.7	2	外傷性膝蓋骨脱臼	著効
13 ペキニーズ	メス	14	5.6	1	股関節形成不全症	無効
14 雑種	メス	6	13.2	1	膝関節炎	有効
15 シェルティー	メス	8	17.0	2	関節炎	無効
16 ポメラニアン	メス	3	3.7	1	膝蓋骨脱臼	有効
17 マルチーズ	避妊	10	4.7	1	関節炎	著効
18 パーニーズ	メス	1	30.0	3	関節炎	著効
19 雑種	オス	5	13.2	1	左後肢跛行	著効
20 柴犬	オス	12	10.5	2	変形性脊椎症	悪化
21 チワワ	去勢	2		1	関節炎	著効
22 雑種	避妊	12	13.3	1	膝蓋骨脱臼	無効
23 ゴールデンレトリバー	メス	5	26.8	2	捻挫	判定不能
24 ダックス	避妊	8	4.3	1	関節炎	やや
25 雑種	避妊	12	8.7	1	変形性脊椎症	著効
26 雑種	去勢	12	15.7	2	変形性脊椎症	判定不能
27 雑種	避妊	9	19.9	2	腰痛	著効
28 バグ	メス	8	7.2	1	変形性脊椎症	無効
29 マルチーズ	メス	18	3.0	1	左肩関節亜脱臼	著効
30 ポメラニアン	避妊	11	6.0	1	両股関節部変形性関節炎	著効
31 雑種	避妊	9	13.2	1	両股関節部変形性関節炎	著効
32 シーズー	去勢	6	8.3	1	右膝蓋骨脱臼	著効
33 ミニチュウアビシニアン	オス	17	1.7	1	左肘関節部変形性関節炎	判定不能
34 ポメラニアン	去勢	7	6.3	1	左肩関節亜脱臼	著効
35 雑種	メス	12	14.1	1	右股関節部及び膝関節部亜脱臼	有効
36 キャバリア	メス	3	7.9	1	左膝関節部亜脱臼	有効

Key to  
Remarks

著効	Clear efficacy	48%
有効	OK efficacy	21%
やや有効	OK	6%
悪化	No effect	3%
無効	No efficacy	21%
判定不能	undecidable	3例

**THE CLAIMS DEFINING THE INVENTION ARE:**

1. A composition for administration to animals including a combination of :
  - (a) at least one anti-inflammatory agent selected from the group comprising
    - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
    - ii) shark cartilage; with
  - (b) at least one enhancing agent selected from the group of:
    - i) a bark product or extract exhibiting antioxidant properties, and
    - ii) shark cartilage;and wherein for a composition including just one member from each group, the selected members must be different.
2. A composition for administration to animals including a combination of :
  - (a) at least one anti-inflammatory agent selected from the group comprising
    - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
    - ii) shark cartilage; with
  - (b) at least one enhancing agent selected from the group of:
    - i) a bark or plant product or extract exhibiting any one of antioxidant, anti-arthritic, and anti-inflammatory properties, and
    - ii) shark cartilage;and wherein for a composition including just one member from each group, the selected members must be different.
3. A composition as claimed in either claim 1 or claim 2 which includes either or both of a green-lipped mussel extract (GLME) and a pharmaceutically active green lipped mussel product, in combination with any one or more of:  
shark cartilage, pharmacologically active shark extract, and chondroitin sulphate.
4. A composition as claimed in either claim 1 or claim 2 which includes an anti-inflammatory agent in combination with a chondroitin compound.

5. A composition as claimed in either claim 1 or claim 2 which includes as the anti-inflammatory agent either or both of shark cartilage and pharmacologically active shark cartilage extract in combination with any one or more of:  
Enzogenol™, Pycnogenol™, a bark extract equivalent to Enzogenol™ or Pycnogenol™, chondroitin sulphate, and a chondroitin compound.
6. A composition as claimed in any one of the preceding claims which includes, as an enhancing agent, Pycnogenol™.
7. A composition as claimed in any one of the preceding claims which includes one or more anti-oxidants other than Enzogenol or equivalent bark extracts.
8. A composition as claimed in claim 7 in which an anti-oxidant is vitamin E.
9. A composition as claimed in any one of the preceding claims which includes deer velvet or a pharmacologically active extract thereof.
10. A composition as claimed in any one of the preceding claims which includes additional glycosaminoglycans than those present in the selected anti-inflammatory or enhancing agents.
11. A composition as claimed in any one of the preceding claims which green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product in sufficient amount to provide gastro-intestinal protection against irritation by other components in the composition.
12. A composition as claimed in any one of the preceding claims which also includes any one or more of the following components:  
a vitamin, glycine, lysine, methionine, glutamic acid, tyrosine, and compounds providing in a pharmacologically acceptable form one or more of the following elements: manganese, zinc, iron, magnesium, selenium, calcium, copper, potassium, cobalt.
13. A composition as claimed in any one of the preceding claims which includes one or more pharmacologically active substances.

14. A composition as claimed in claim 13 in which a pharmacologically active substance is an anti-inflammatory other than those listed in claim 1.
15. A composition as claimed in any one of the preceding claims formulated to be suitable for addressing any one or more of the following conditions in animals: inflammation, arthritis, chronic joint pain.
16. A composition as claimed in any one of the preceding claims in any one or more of the following forms:  
  
as a bolus or tablet, in a capsule, as a slow release implant, as a liquid composition, as a gel, and as a paste.
17. A composition as claimed in any one of the preceding claims formulated for use with non-human mammals.
18. A method for addressing joint problems in non-human animals consisting of the administration of a composition as claimed in any one of the preceding claims.
19. A method as claimed in claim 18 in which the method of administration is oral.
20. A composition substantially as described herein with reference to the contained examples.
21. A method for addressing joint problems, substantially as described herein with reference to the contained examples.
22. The use of any two or more of:
  - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product,
  - ii) shark cartilage and/or pharmacologically active shark cartilage extract;  
and
  - iii) an antioxidant bark extract,in the preparation of a composition for use in addressing any one or more of:
  - a) inflammation;
  - b) degenerative joint complaints;
  - c) other cartiligenous degeneration;
  - d) gastrointestinal sensitivity or irritation;
  - e) cancerous tumours;

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/NZ 00/00135

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K35/56 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, FSTA, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 199745 Derwent Publications Ltd., London, GB; Class B04, AN 1997-487854 XP002154177 &amp; NZ 270 754 A (MCFARLANE LAB NZ LTD), 22 August 1997 (1997-08-22) abstract</p> <p>-----</p>	1

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

29 November 2000

Date of mailing of the international search report

11/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

# INTERNATIONAL SEARCH REPORT

### Information on patent family members

Inter: **1st Application No**

PCT/NZ 00/00135

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
NZ 270754	A	22-08-1997	NONE

REVISED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number  
**WO 01/05411 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 35/56**, A61P 29/00 (74) Agents: SIMS, Anthony, W. et al.; 29 Clarence Street, Private Bag 3140, Hamilton 2001 (NZ).
- (21) International Application Number: PCT/NZ00/00135 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 21 July 2000 (21.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
336856 21 July 1999 (21.07.1999) NZ  
500630 27 October 1999 (27.10.1999) NZ  
505875 21 July 2000 (21.07.2000) NZ
- (71) Applicant (*for all designated States except US*): BOMAC LABORATORIES LIMITED [NZ/NZ]; 102 Wiri Station Road and Hobill Avenue, Manukau City, Auckland 1701 (NZ).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): HASHMI, Syed, Ziauddin [NZ/NZ]; 31 Watson Place, Papatoetoe, Auckland 1701 (NZ). LEECH, Wayne, Frederick [NZ/NZ]; 2 Rochas Place, Manukau City, Auckland 1701 (NZ). MCLAREN, Donald, George [NZ/NZ]; 2 Turangi Road, Whitford, Auckland 1750 (NZ). MCSPORRAN, Keith, David [NZ/NZ]; 26c Peary Road, Mount Eden, Auckland 1003 (NZ).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— With international search report.
- (88) Date of publication of the revised international search report: 31 May 2001
- (15) Information about Correction:  
see PCT Gazette No. 22/2001 of 31 May 2001, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS ADDRESSING INFLAMMATION AND/OR DEGENERATIVE DISORDERS

(57) Abstract: The present invention is directed to compositions for primarily addressing degenerative complaints - in particular joint related conditions, such as arthritis and rheumatism, in which there may also be associated inflammation. Other potential uses are also discussed, as well as prophylactic and curative applications. Preferred embodiments incorporate green-lip mussel products (particularly GLME) with shark cartilage or chondroitin compounds. Plant and bark based antioxidants are employed in a number of embodiments.

WO 01/05411 A1

REVISED  
VERSION

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NZ 00/00135

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K35/56 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, FSTA, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199745 Derwent Publications Ltd., London, GB; Class B04, AN 1997-487854 XP002154177 & NZ 270 754 A (MCFARLANE LAB NZ LTD), 22 August 1997 (1997-08-22) abstract -----	1

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*B\* document member of the same patent family

Date of the actual completion of the international search

17 January 2001

Date of making of the international search report

18. 01. 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/NZ 00/00135

## **B x I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **18, 19, 21**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## **Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 18,19,21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Claims Nos.: 18,19,21

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

International Application No

PCT/NZ 00/00135

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
NZ 270754      A	22-08-1997	NONE	
-----			

19 SEP 2001

COPY

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

JAMES & WELLS  
Private Bag 3140  
HAMILTON  
New Zealand

**PCT**

NOTIFICATION OF TRANSMITTAL OF  
INTERNATIONAL PRELIMINARY EXAMINATION  
REPORT

(PCT Rule 71.1)

Date of mailing  
day/month/year

**12 SEP 2001**

Applicant's or agent's file reference  
18040/29las

**IMPORTANT NOTIFICATION**

International Application No.  
**PCT/NZ00/00135**

International Filing Date  
21 July 2000

Priority Date  
21 July 1999

Applicant

**BOMAC LABORATORIES LIMITED et al**

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translations to those Offices.

**4. REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide

Name and mailing address of the IPEA/AU

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
E-mail address: [pct@ipaaustralia.gov.au](mailto:pct@ipaaustralia.gov.au)  
Facsimile No. (02) 6285 3929

Authorized officer

**SHUBHRA CHANDRA**  
Telephone No. (02) 6283 2264

**PATENT COOPERATION TREATY**  
**PCT**  
**INTERNATIONAL PRELIMINARY EXAMINATION REPORT**  
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 18040/4X104	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. <b>PCT/NZ00/00135</b>	International Filing Date ( <i>day/month/year</i> ) 21 July 2000	Priority Date ( <i>day/month/year</i> ) 21 July 1999
International Patent Classification (IPC) or national classification and IPC  Int. Cl. <sup>7</sup> A61K35/56, A61P 29/00, 35/00		
Applicant  BOMAC LABORATORIES LIMITED et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																								
2.	This REPORT consists of a total of 4 sheets, including this cover sheet.  <input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).  These annexes consist of a total of / sheet(s).																								
3. This report contains indications relating to the following items:  <table style="width: 100%; border: none;"> <tr> <td style="width: 5%;">I</td> <td style="width: 5%; text-align: center;"><input checked="" type="checkbox"/></td> <td>Basis of the report</td> </tr> <tr> <td>II</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Priority</td> </tr> <tr> <td>III</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Lack of unity of invention</td> </tr> <tr> <td>V</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Certain documents cited</td> </tr> <tr> <td>VII</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td>Certain observations on the international application</td> </tr> </table>		I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input checked="" type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																							
II	<input type="checkbox"/>	Priority																							
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
IV	<input type="checkbox"/>	Lack of unity of invention																							
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
VI	<input type="checkbox"/>	Certain documents cited																							
VII	<input type="checkbox"/>	Certain defects in the international application																							
VIII	<input checked="" type="checkbox"/>	Certain observations on the international application																							

Date of submission of the demand 22 December 2000	Date of completion of the report 6 September 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: <a href="mailto:pct@ipaustalia.gov.au">pct@ipaustalia.gov.au</a> Facsimile No. (02) 6285 3929	Authorized Officer  <b>SHUBHRA CHANDRA</b> Telephone No. (02) 6283 2264

**I. Basis of the report**

1. With regard to the elements of the international application:\*
- ☐ the international application as originally filed.
- ☒ the description, pages 1-24, as originally filed,  
pages , filed with the demand,  
pages , received on with the letter of
- ☒ the claims, pages 26-27, as originally filed,  
pages , as amended (together with any statement) under Article 19,  
pages , filed with the demand,  
pages 25, received on 18 May 2001 with the letter of 18 May 2001(See boxVIII)
- ☐ The drawings, pages , as originally filed,  
pages , filed with the demand,  
pages , received on with the letter of
- ☐ The sequence listing part of the description:  
pages , as originally filed  
pages , filed with the demand  
pages , received on with the letter of
2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  
These elements were available or furnished to this Authority in the following language which is:
- ☐ The language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ The language of publication of the international application (under Rule 48.3(b)).
- ☐ The language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).
3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
- ☐ Contained in the international application in written form.
- ☐ Filed together with the international application in computer readable form.
- ☐ Furnished subsequently to this Authority in written form.
- ☐ Furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished
4. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.
5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims 1-22	YES
	Claims	NO
Inventive step (IS)	Claims 1-22	YES
	Claims	NO
Industrial applicability (IA)	Claims 1-22	YES
	Claims	NO

**2. Citations and explanations (Rule 70.7)****Novelty (N) and Inventive Step (IS) Claims 1-22**

Amended claims are novel and inventive in the light of the citation NZ 270754 A (MCFARLANE LAB NZ LTD) DERWENT AN 1997-487854.

The citation does not disclose the composition comprising an anti-arthritis agent selected from green-lipped mussel extract (GLME) and shark cartilage and an enhancing agent selected from bark extract, chondroitin compound, deer velvet and vitamin E.

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The amended page filed on 18 May 2001 should be 25 not 22 as currently on the file.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/NZ 00/00135

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K35/56 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, FSTA, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199745 Derwent Publications Ltd., London, GB; Class B04, AN 1997-487854 XP002154177 & NZ 270 754 A (MCFARLANE LAB NZ LTD), 22 August 1997 (1997-08-22) abstract	1

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

29 November 2000

Date of mailing of the international search report

11/12/2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NZ 00/00135

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
NZ 270754 A	22-08-1997	NONE	

PCT

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>18040/4PCX104</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/NZ-00/ 00135</b>	International filing date (day/month/year) <b>21/07/2000</b>	(Earliest) Priority Date (day/month/year) <b>21/07/1999</b>
Applicant  <b>BOMAC LABORATORIES LIMITED et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claims 1-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Continuation of Box I.1

Claims Nos.: 1-19

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/NZ 00/00135

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K35/56 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, FSTA, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 199745 Derwent Publications Ltd., London, GB; Class B04, AN 1997-487854 XP002154177 &amp; NZ 270 754 A (MCFARLANE LAB NZ LTD), 22 August 1997 (1997-08-22) abstract</p> <p>-----</p>	1

☐

Further documents are listed in the continuation of box C.

☐

Patent family members are listed in annex.

\* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* & \* document member of the same patent family

Date of the actual completion of the international search

29 November 2000

Date of mailing of the international search report

11/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NZ 00/00135

Patent document  
cited in search report

Publication  
date

Patent family  
member(s)

Publication  
date

NZ 270754

A

22-08-1997

NONE

- new version -

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>18040/4PCX104</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/NZ 00/ 00135</b>	International filing date (day/month/year) <b>21/07/2000</b>	(Earliest) Priority Date (day/month/year) <b>21/07/1999</b>
Applicant <b>BOMAC LABORATORIES LIMITED et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/NZ 00/00135

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K35/56 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, FSTA, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199745 Derwent Publications Ltd., London, GB; Class B04, AN 1997-487854 XP002154177 & NZ 270 754 A (MCFARLANE LAB NZ LTD), 22 August 1997 (1997-08-22) abstract -----	1

☐ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

17 January 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/NZ 00/00135

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **18, 19, 21**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 18,19,21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Claims Nos.: 18,19,21

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

### Information on patent family members

Internal Application No

PCT/NZ 00/00135

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
NZ 270754      A	22-08-1997	NONE	